Testing immune cells to fight advanced breast cancer

Plain-English translation of NCT07510802 on ClinicalTrials.gov ↗ · Source last updated April 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing a new type of cell therapy called , which are immune cells taken from donors, engineered in the lab to recognize cancer cells, and then given back to patients. The goal is to see if this treatment can help people with advanced breast cancer that has not responded to standard treatments. The therapy targets specific markers on cancer cells to help the immune system find and destroy them.

Many patients with advanced breast cancer run out of treatment options or their cancer stops responding to current therapies. This medication is designed to give the immune system a new way to fight cancer by using natural killer cells—special immune cells that can recognize and kill abnormal cells—and enhancing them to work even better against breast cancer.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic breast cancer that is either HER2-positive or triple-negative
your cancer has gotten worse despite standard treatments, or you are unable to tolerate or receive standard therapy
your cancer has at least one measurable tumor and expresses one of the target markers (HER2, MUC1, or ROR1)
you are in good enough overall health to receive the treatment (performance status 0-1)
your heart, kidney, liver, and blood counts are working well enough to safely receive the therapy

You likely don't qualify if…

you have untreated cancer that has spread to your brain or spinal fluid
you have received another type of engineered cell therapy (like CAR-T) within the last 6 months
you have an active autoimmune disease that requires ongoing immunosuppressive medications
you have an uncontrolled infection, including untreated HIV, hepatitis B, or hepatitis C
you are pregnant, breastfeeding, or unable to use effective birth control for 6 months after treatment

What participation looks like

First, your tumor will be tested to see which markers it carries—this determines which version of the therapy is right for you. You will then receive two chemotherapy drugs (fludarabine and cyclophosphamide) to prepare your body, followed by a single infusion of the engineered immune cells through an IV. After that, you will have regular follow-up visits and scans to monitor how well the treatment is working and manage any side effects. The study involves a dose-escalation phase to find the safest dose, followed by an expansion phase that focuses on specific types of breast cancer.

AI-generated summary from trial data · Jul 15, 2026 · Not medical advice

Trial locations(1 site)

China

Peking University Shenzhen Hospital, Shenzhen, Guangdong